Published in Neuroimage on January 24, 2013
Arterial stiffness and β-amyloid progression in nondemented elderly adults. JAMA Neurol (2014) 1.63
Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study. Lancet Neurol (2015) 1.62
Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain (2014) 1.33
Pulse wave velocity is associated with β-amyloid deposition in the brains of very elderly adults. Neurology (2013) 1.18
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement (2014) 1.14
Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome. Brain (2014) 0.94
Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Mol Psychiatry (2014) 0.89
Cognitive aging in persons with minimal amyloid-β and white matter hyperintensities. Neuropsychologia (2013) 0.88
Markers of cholesterol transport are associated with amyloid deposition in the brain. Neurobiol Aging (2013) 0.87
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Amyloid-β Imaging in Older Adults Presenting to a Memory Clinic with Subjective Cognitive Decline: A Pilot Study. J Alzheimers Dis (2015) 0.85
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement (2015) 0.84
Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease. Ann Neurol (2016) 0.82
Comparison of qualitative and quantitative imaging characteristics of [(11)C]PiB and [(18)F]flutemetamol in normal control and Alzheimer's subjects. Neuroimage Clin (2015) 0.82
Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin (2016) 0.78
Relative 11C-PiB Delivery as a Proxy of Relative CBF: Quantitative Evaluation Using Single-Session 15O-Water and 11C-PiB PET. J Nucl Med (2015) 0.77
Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. Alzheimers Dement (Amst) (2017) 0.76
Amyloid-Beta Deposition is Associated with Increased Medial Temporal Lobe Activation during Memory Encoding in the Cognitively Normal Elderly. Am J Geriatr Psychiatry (2017) 0.75
Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome. Neurobiol Aging (2017) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
Mild cognitive impairment as a diagnostic entity. J Intern Med (2004) 26.95
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
[11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology (2006) 12.10
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
High agreement but low kappa: II. Resolving the paradoxes. J Clin Epidemiol (1990) 8.28
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Imaging beta-amyloid burden in aging and dementia. Neurology (2007) 7.70
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Age, neuropathology, and dementia. N Engl J Med (2009) 6.36
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain (2008) 6.29
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging (2010) 5.49
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
A framework for feature selection in clustering. J Am Stat Assoc (2010) 3.46
Longitudinal cognitive decline is associated with fibrillar amyloid-beta measured by [11C]PiB. Neurology (2010) 2.92
11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology (2007) 2.65
PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology (2007) 2.63
A re-analysis of the reliability of psychiatric diagnosis. Br J Psychiatry (1974) 2.48
Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med (1999) 2.30
Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology (2010) 1.99
Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci (2009) 1.89
3D PIB and CSF biomarker associations with hippocampal atrophy in ADNI subjects. Neurobiol Aging (2010) 1.70
Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage (2011) 1.64
Visual assessment versus quantitative assessment of 11C-PIB PET and 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med (2007) 1.60
Pittsburgh compound B (11C-PIB) and fluorodeoxyglucose (18 F-FDG) PET in patients with Alzheimer disease, mild cognitive impairment, and healthy controls. J Geriatr Psychiatry Neurol (2010) 1.24
Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiol Aging (2010) 1.19
In vivo assessment of amyloid-β deposition in nondemented very elderly subjects. Ann Neurol (2013) 1.17
Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage (2010) 1.13
Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry (2010) 0.97
Visual assessment of [(11)C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging (2010) 0.93
Sparse Clustering with Resampling for Subject Classification in PET Amyloid Imaging Studies. IEEE Nucl Sci Symp Conf Rec (1997) (2011) 0.78
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
A randomized trial of protocol-based care for early septic shock. N Engl J Med (2014) 16.05
Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med (2012) 14.14
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke (2011) 10.11
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain (2008) 9.64
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Use of intensive care at the end of life in the United States: an epidemiologic study. Crit Care Med (2004) 9.06
Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol (2008) 7.95
Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain (2007) 6.39
Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab (2005) 6.25
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain (2008) 5.89
Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. Arch Intern Med (2007) 5.65
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem (2003) 5.34
Genomewide association studies of stroke. N Engl J Med (2009) 5.29
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med (2005) 5.10
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Developing a national strategy to prevent dementia: Leon Thal Symposium 2009. Alzheimers Dement (2010) 4.85
Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease. Ann Neurol (2011) 4.38
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol (2007) 4.11
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet (2002) 3.88
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. J Neurol Neurosurg Psychiatry (2010) 3.66
Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry (2006) 3.61
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med (2008) 3.44
Incidence and prevalence of dementia in the Cardiovascular Health Study. J Am Geriatr Soc (2004) 3.43
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry (2004) 3.17
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Physical activity, APOE genotype, and dementia risk: findings from the Cardiovascular Health Cognition Study. Am J Epidemiol (2005) 3.10
The long-term effects of conventional and atypical antipsychotics in patients with probable Alzheimer's disease. Am J Psychiatry (2013) 3.06
Brain structure and obesity. Hum Brain Mapp (2010) 3.04
Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology (2003) 2.97
Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry (2004) 2.87
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Angiotensin-converting enzyme inhibitors and cognitive decline in older adults with hypertension: results from the Cardiovascular Health Study. Arch Intern Med (2009) 2.82
Psychiatric disorders among bariatric surgery candidates: relationship to obesity and functional health status. Am J Psychiatry (2007) 2.80
Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A (2005) 2.79
Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol (2009) 2.79
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Mild cognitive impairment and alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology (2009) 2.70
3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage (2006) 2.69
Dementia with Lewy bodies. Lancet Neurol (2004) 2.66
Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol (2009) 2.66
End-of-life care for the critically ill: A national intensive care unit survey. Crit Care Med (2006) 2.61
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA (2009) 2.59
Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. JAMA (2013) 2.58
Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci (2008) 2.57
Harmonizing international trials of early goal-directed resuscitation for severe sepsis and septic shock: methodology of ProCESS, ARISE, and ProMISe. Intensive Care Med (2013) 2.44
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Effect of APOE ε4 status on intrinsic network connectivity in cognitively normal elderly subjects. Arch Neurol (2011) 2.40
Genome-wide association studies of cerebral white matter lesion burden: the CHARGE consortium. Ann Neurol (2011) 2.37
Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci (2008) 2.30